- Trial phase
- Approved
- Time to market
- Already approved and marketed since December 2014; continuous label expansions ongoing
- Why 4/10
- Opdivo is already approved and generating ~$10B in annual revenue; the most recent binary catalyst (cHL label expansion PDUFA) was approved on March 20, 2026, with no new hard-dated PDUFA or pivotal readout for Opdivo in the next ~12 months. As an approved, commercially mature product in a large-cap diversified pharma, impactScore is 4, label-expansion events and quarterly sales beats are incremental, not binary.
Opdivo is a cash-cow mega-blockbuster with steady ~$10B/year revenue, but BMY stock is driven more by the broader pipeline (iberdomide PDUFA Aug 17, 2026), the patent cliff on Eliquis and Opdivo, and the growth of newer products (Camzyos, Breyanzi, Cobenfy). Investors should watch Opdivo's quarterly sales trajectory for erosion signs as biosimilar competition approaches (US patent cliff ~2028) and track BMY's ability to offset with the subcutaneous Opdivo Qvantig launch and new indications.
Price Chart
Executive Summary
Opdivo (nivolumab) is Bristol-Myers Squibb's blockbuster PD-1 inhibitor immunotherapy, approved since 2014 across ~12 different cancer types including melanoma, lung cancer, kidney cancer, Hodgkin lymphoma, and liver cancer. It generated $9.30 billion in 2024 sales (+3% YoY) and ~$10.0 billion in 2025, making it BMY's second-largest drug behind Eliquis. Opdivo competes head-to-head with Merck's Keytruda (which dominates the PD-1 market with >50% share). The drug faces a looming patent cliff, EU patent expiry around 2026 and US expiry around 2028, with biosimilar development underway by Amgen, Sandoz, and others. BMY is attempting to extend Opdivo's franchise with a subcutaneous formulation (Opdivo Qvantig) and new combination approvals. For BMY investors, Opdivo is a mature cash cow whose slow erosion will need to be backfilled by BMY's Growth Portfolio (Camzyos, Breyanzi, Cobenfy, iberdomide).
How It Works
Opdivo is an immunotherapy (a PD-1 immune checkpoint inhibitor). It works by blocking a protein called PD-1 on the surface of immune T-cells. This "releases the brakes" on the immune system, allowing the body's own T-cells to recognize and attack cancer cells more effectively.
Trial Status
Opdivo is FDA-approved across ~12 cancer indications. Latest approval was March 20, 2026 (nivolumab + AVD chemotherapy for previously untreated Stage III/IV classical Hodgkin lymphoma). A subcutaneous formulation (Opdivo Qvantig) was approved December 27, 2024. Additional Phase 2/3 combination studies continue across multiple tumor types.
The Two-Sided Case
Upcoming Catalysts
- Quarterly sales reports tracking Opdivo revenue trajectory vs consensus expectations
- Ongoing label expansion decisions from FDA and EMA for combination regimens
- Biosimilar competitive developments (Amgen IPR decisions, Sandoz JPB898 trial results, Zydus market entry)
- SubQ formulation (Opdivo Qvantig) commercial adoption and payer coverage decisions
- BMY earnings reports (next expected mid-2026) with Growth Portfolio vs Legacy Portfolio mix update
Source Filing
The SEC filing that triggered this drug report: